VEGFR2/CD309 抗体
Our Local Distributor
北京 101111
Quick Overview for VEGFR2/CD309 抗体 (ABIN2745581)
抗原
See all VEGFR2/CD309 (VEGFR2) 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
特异性
- The antibody will detect native human VEGFR-2/KDR in ELISA experiments and on the surface of different human cell types.
-
交叉反应
- 人
-
纯化方法
- Protein G purified.
-
免疫原
- Recombinant human soluble extracellular VEGFR-2.
-
亚型
- IgG1
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Centrifuge vial prior to opening. Reconstitute with sterile water to a concentration of 0.1-1.0 mg/mL.
-
浓度
- Lot specific
-
缓冲液
- Lyophilized.
-
储存条件
- 4 °C,-20 °C
-
储存方法
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C. -
有效期
- 6 months
-
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
别名
- VEGFR-2/KDR
-
背景
- Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels, modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.
-
UniProt
- P35968
-
途径
- RTK signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
抗原
-